Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014

By Jon E. Zibbell, A. Asher, Rajiv C Patel, Benjamin A. Kupronis, K. Iqbal, J. Ward, D. Holtzman. American Journal of Public Health, 2018

638 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/76649e07024ab3b7cb8e8dee9ea564f6132ebb01

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Aghemo
2. G. Dusheiko
3. M. Puoti
4. J. Pawlotsky

In Hepatology

1. A. Aghemo
2. G. Dusheiko
3. M. Puoti
4. J. Pawlotsky

Citations in the corpus

• EASL recommendations on treatment of hepatitis C - Final update of the series. (2020, result): “as a result of the “opioid epidemic” and high rates of mortality on thewaiting list, have startedusingHCVRNA-positive livers fornoninfected liver and kidney graft recipients, with good preliminary results.(207,212) In a recent study, early liver graft outcomes were similar in recipients of HCV RNA-p”
• The Rise of Illicit Fentanyls, Stimulants and the Fourth Wave of the Opioid Overdose Crisis (2021, background): “A twofold increase in acute hepatitis C (HCV) rates nationally was seen as corresponding to the rise in treatment admissions for OUD during the first two waves of the opioid overdose epidemic [79].”
• Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder (2020, methodology): “EXPOSURES One of 6 mutually exclusive treatment pathways, including (1) no treatment, (2) inpatient detoxification or residential services, (3) intensive behavioral health, (4) buprenorphine or methadone, (5) naltrexone, and (6) nonintensive behavioral health.”